Latest "irbesartan amlodipine irbesartan Hypertension" News Stories

06:37 EDT 30th March 2015 | BioPortfolio

Here are the most relevant search results for "irbesartan amlodipine irbesartan Hypertension" found in our extensive news archives from over 250 global news sources.

More Information about irbesartan amlodipine irbesartan Hypertension on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about irbesartan amlodipine irbesartan Hypertension for you to read. Along with our medical data and news we also list irbesartan amlodipine irbesartan Hypertension Clinical Trials, which are updated daily. BioPortfolio also has a large database of irbesartan amlodipine irbesartan Hypertension Companies for you to search.

Showing "irbesartan amlodipine irbesartan Hypertension" News Articles 1–25 of 931

Extremely Relevant

Human medicines European public assessment report (EPAR): Irbesartan Zentiva (previously Irbesartan Winthrop), irbesartan, Revision: 15, Authorised

Human medicines European public assessment report (EPAR): Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop), irbesartan / hydrochlorothiazide, Revision: 19, Authorised

Human medicines European public assessment report (EPAR): Irbesartan Teva, irbesartan, Revision: 6, Authorised

Human medicines European public assessment report (EPAR): Ifirmasta (previously Irbesartan Krka), irbesartan, Revision: 5, Authorised

Human medicines European public assessment report (EPAR): Irbesartan/Hydrochlorothiazide Teva, irbesartan / hydrochlorothiazide, Revision: 7, Authorised

Human medicines European public assessment report (EPAR): Sabervel, irbesartan, Revision: 2, Authorised

Human medicines European public assessment report (EPAR): Aprovel, irbesartan, Revision: 32, Authorised

Human medicines European public assessment report (EPAR): Karvea, irbesartan, Revision: 31, Authorised

Human medicines European public assessment report (EPAR): Ifirmacombi, irbesartan / hydrochlorothiazide, Revision: 2, Authorised

Human medicines European public assessment report (EPAR): CoAprovel, irbesartan / hydrochlorothiazide, Revision: 30, Authorised

Human medicines European public assessment report (EPAR): Karvezide, irbesartan / hydrochlorothiazide, Revision: 31, Authorised

FDA Approves Prestalia (amlodipine and perindopril) for Hypertension

January 21, 2015 -- Symplmed Pharmaceuticals announced that on January 21, 2015 the U.S. Food and Drug Administration approved Prestalia, a fixed dose combination of perindopril and amlodipine for the treatment of hypertension. Symplmed is excited...

Relevant

Simultaneous Determination of Amlodipine and Its Counterion Besylate

Thermo Fisher Scientific has developed a simple, rapid, reliable, and accurate high-performance liquid chromatography (HPLC) method for the simultaneous determination of amlodipine and besylate in an amlodipine besylate drug substance.

FDA approves Symplmed's Prestalia combo for hypertension

Symplmed Pharmaceuticals LLC (Cincinnati, Ohio) said FDA approved an NDA for Prestalia to treat hypertension. The company plans to launch the fixed-dose combination of perindopril arginine plus amlodipine besylate this quarter through its bpCareConne...

Par Pharmaceutical Begins Shipment of Generic Exforge®

WOODCLIFF LAKE, N.J., Sept. 30, 2014 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that it has begun shipping all four strengths of amlodipine and valsartan tablets, the generic version of Novartis' Exforge®.  Par received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for amlodipine and valsartan and was grant...

FDA Approves Symplmed's Prestalia® for Treatment of Hypertension

Symplmed Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has approved Prestalia® (perindopril arginine and amlodipine) tablets, licensed from Servier (Suresnes, France), for the treatment of hypertension. Prestalia, th...

Symplmed Pharmaceuticals approved for Prestalia

Ryan ChavisSymplmed Pharmaceuticals announced that the Food and Drug Administration approved Prestalia (perindopril arginine and amlodipine) tablets to treat hypertension.  read more

US FDA approves Symplmed and Servier’s Prestalia

Privately-held US drugmaker Symplmed Pharmaceuticals says that the US Food and Drug Administration has approved Prestalia (perindopril arginine and amlodipine) tablets for the treatment of hypertension.

FDA Approvals, In Brief: Novartis’ Meningitis Vaccine Bexsero Gets Early Nod

Also, Rockwell’s iron deficiency treatment Triferic gains agency approval, but without a dose-sparing claim related to erythropoiesis-stimulating agents; Symplmed’s perindopril/amlodipine fixed-dose combination approved for hypertension.

Attitudes and preferences for the clinical management of hypertension and hypertension-related cardiac disease in general practice: results of the Italian Hypertension and Heart Survey

Interventional Management in Hypertension

What types of device-based interventions to lower drug-resistant hypertension have been developed over the last number of years, and how effective are they? Current Opinion in Nephrology and Hypertension

Undiagnosed hypertension more likely in rheumatoid arthritis

(HealthDay)—Among patients meeting guideline-based criteria for hypertension, those with rheumatoid arthritis (RA) are less likely to receive a diagnosis of hypertension, according to a study published in the September issue of Arthritis Care & Res...

Hypertension Partnering 2009-2014

Recently added to the BioPortfolio report store, Hypertension Partnering 2009-2014 is a new report from Current Partnering published on 2014-10-31. This 100+-page report is available from $995. The Hypertension Partnering 2009-2014 report provides understanding and access to the hypertension partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in hypert...

Prestalia perindopril/amlodipine regulatory update

Chronic insomniacs may face increased risk of hypertension

Insomniacs who take longer than 14 minutes to fall asleep face a greater risk of hypertension, according to new research in the American Heart Association journal Hypertension.


Search BioPortfolio:
Loading
Advertisement
Advertisement

News Quicklinks